Latest Conference Articles

Afreen Shariff, MD, MBBS, Duke Cancer Institute, discusses the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.

The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.

The American Society of Nephrology (ASN) Kidney Week 2023 will take place in Philadelphia, Pennsylvania, from November 2-5, as experts from across the globe gather to discuss the latest innovations in renal care and current issues facing the field.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed cost savings that occurred so far from their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health and also noted those they predict to occur as the program continues.

April Armstrong, MD, MPH, of University of California, Los Angeles, discussed how recent biologics advancements improved moderate-to-severe atopic dermatitis (AD) treatment.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, provides an overview of their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, discussing the program's origin, objectives, and beyond.

The phase 4 ANNEXA-I trial was stopped early after showing superior hemostatic efficacy and the capability to limit potentially life-threatening intracerebral hemorrhage (ICH) compared with usual care in patients taking oral factor Xa (FXa) inhibitors.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, provides on overview of the treatment landscape in patients with skin of color with plaque psoriasis.

Through the integration of a population health reimbursement model in 2020, Allina Health Cancer Institute was able to implement expanded screening initiatives through the use of artificial intelligence and precision medicine, according to Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health.

A poster presented at AMCP Nexus 2023 reported that payers believe implementing the Inflation Reduction Act (IRA) will impact Medicare Part D plans financially.

Landon Marshall, PharmD, PhD, of Prime Therapeutics, discusses the benefits of gene therapy forecasting for health insurers and what future advancements can be expected.

MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib.

Timothy O'Shea, PharmD, MS, discussed the most surprising findings from a home infusion pilot program and explained how he thinks home infusion will continue to evolve.

Helen Shih, MD, MS, MPH, FASTRO, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.

Tina Cascone, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses the impact of the CheckMate 77T study on the treatment approach for non–small cell lung cancer (NSCLC).

Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention therapy had less toxicity.

Psoriasis status from time of diagnosis to initiation of current treatment was less favorable for patients with mild psoriasis compared with moderate psoriasis, according to one study.

Christina Barrington, PharmD, of Priority Health, explained the keys to leading a successful managed care organization, as well as where she predicts the industry will be in the future.

Thomas Powles, MD, MBBS, MRCP, from Barts Cancer Centre, shares insights from the EV-302/KEYNOTE-A39 trial and its implications for the future of enfortumab vedotin and pembrolizumab (EV+P) combination therapy for urothelial carcinoma.

Enfortumab vedotin plus pembrolizumab not only beat chemotherapy in the first-line setting for locally advanced metastatic urothelial cancer for the first time in decades, but it nearly doubled progression-free survival and overall survival vs chemotherapy.

There are many drugs that have been around for years and others with strong data awaiting FDA approval that are beneficial in treating conditions like atopic dermatitis and alopecia areata, said James Q. Del Rosso, DO.

Posters presented at Fall Clinical Dermatology 2023 found that dupilumab had effective and safe results when received in a 5-year period for atopic dermatitis.

A panel discussion that took place at the 2023 Fall Clinical Dermatology Conference focused on the importance of information to treat both vitiligo and atopic dermatitis.

Regardless of presence of brain metastases, patients with HER2-mutant (HER2m) non–small cell lung cancer (NSCLC) showed systemic responses to trastuzumab deruxtecan. In addition, the therapy showed intracranial efficacy to reduce the size of brain metastases.

The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.

With stringent criteria, randomized controlled trials are the cornerstone of cancer intervention research, but the result is they do not represent the majority of patients, which leads to a gap between the efficacy seen in trials and the effectiveness in the real-world setting.

Patients with alopecia areata found effective treatment with baricitinib, which had long-term efficacy and positive results.

Kevin Kalinsky, MD, MS, of Glenn Family Breast Center, gives insight into the real-world data supporting the use of sacituzumab govitecan-hziy in the treatment of triple-negative breast cancer (TNBC).